Text and Data Mining valid from 2017-10-13
First Online: 13 October 2017
: The authors declare that I.-K.P. has received honoraria for speaking at scientific meetings, serving on scientific advisory boards and consulting activities from Adamas Pharma, Bayer Pharma, Biogen, Genzyme, Merck Serono, Novartis, Roche, Teva Pharmaceuticals; and that she has received research support from Novartis, the German Multiple Sclerosis Society, and Teva Pharmaceuticals. F.P. declares that he has served on scientific advisory boards for MedImmune and Novartis; received speaker honoraria and travel funding from Alexion, Bayer, Biogen Idec, Chugai, MedImmune, Merck Serono, Novartis, Sanofi-Aventis/Genzyme, Teva Pharmaceuticals, and Shire; is an academic editor of <i>PLoS ONE</i> and an associate editor of <i>Neurology Neuroimmunology & Neuroinflammation</i>; has consulted for Alexion, Biogen Idec, MedImmune, Sanofi-Aventis/Genzyme and Shire; and received research support from Alexion, Arthur Arnstein Stiftung Berlin, Bayer, Biogen Idec, EU FP7 Framework Program, German Ministry of Education and Research, German Research Council, Guthy-Jackson Charitable Foundation, Merck Serono, National Multiple Sclerosis Society of the USA, Novartis, Sanofi-Aventis/Genzyme, Teva Pharmaceuticals, and Werth Stiftung of the City of Cologne.